592
Views
15
CrossRef citations to date
0
Altmetric
Original Articles

Conditioning regimen intensity and low-dose azacitidine maintenance after allogeneic hematopoietic cell transplantation for acute myeloid leukemia

, , , , , , , , , , , , , , , & show all
Pages 2839-2849 | Received 16 Apr 2020, Accepted 25 Jun 2020, Published online: 10 Jul 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Tingting Pan, Shiyu Han, Meng Zhou, Jiaqian Qi, Hong Wang, Xiaoyan Xu, Xueqian Li, Yifang Yao & Yue Han. (2022) Efficacy of azacitidine in preventing relapse after hematopoietic stem cell transplantation for advanced myeloid malignancies: a systematic review and meta-analysis. Expert Review of Hematology 15:5, pages 457-464.
Read now
Jonathan A. Webster, Meera Yogarajah, Marianna Zahurak, Heather Symons, Amy E. Dezern, Ivana Gojo, Gabrielle T. Prince, Jillian Morrow, Richard J. Jones, B. Douglas Smith & Margaret Showel. (2021) A phase II study of azacitidine in combination with granulocyte-macrophage colony-stimulating factor as maintenance treatment, after allogeneic blood or marrow transplantation in patients with poor-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Leukemia & Lymphoma 62:13, pages 3181-3191.
Read now

Articles from other publishers (13)

Yuho Najima. (2023) Overcoming relapse: prophylactic or pre-emptive use of azacitidine or FLT3 inhibitors after allogeneic transplantation for AML or MDS. International Journal of Hematology 118:2, pages 169-182.
Crossref
Daniel Weisdorf. (2022) Allogeneic transplantation for advanced acute leukemia. Hematology 2022:1, pages 534-538.
Crossref
Yuho Najima, Takayoshi Tachibana, Yusuke Takeda, Yuya Koda, Yasuhisa Aoyama, Takashi Toya, Aiko Igarashi, Masatsugu Tanaka, Emiko Sakaida, Ryohei Abe, Makoto Onizuka, Takeshi Kobayashi, Noriko Doki, Kazuteru Ohashi, Heiwa Kanamori, Takuma Ishizaki, Akira Yokota, Satoshi Morita, Shinichiro Okamoto & Yoshinobu Kanda. (2022) Dose-finding trial of azacitidine as post-transplant maintenance for high-risk MDS: a KSGCT prospective study. Annals of Hematology 101:12, pages 2719-2729.
Crossref
Guancui Yang, Xiang Wang, Shiqin Huang, Ruihao Huang, Jin Wei, Xiaoqi Wang & Xi Zhang. (2022) Generalist in allogeneic hematopoietic stem cell transplantation for MDS or AML: Epigenetic therapy. Frontiers in Immunology 13.
Crossref
Steven A. Manobianco, Tara Rakiewicz, Lindsay Wilde & Neil D. Palmisiano. (2022) Novel Mechanisms for Post-Transplant Maintenance Therapy in Acute Myeloid Leukemia. Frontiers in Oncology 12.
Crossref
Kevin-James Wattebled, Elodie Drumez, Valérie Coiteux, Léonardo Magro, Micha Srour, Paul Chauvet, Bruno Quesnel, Alain Duhamel, Ibrahim Yakoub-Agha & David Beauvais. (2022) Single-agent 5-azacytidine as post-transplant maintenance in high-risk myeloid malignancies undergoing allogeneic hematopoietic cell transplantation. Annals of Hematology 101:6, pages 1321-1331.
Crossref
Jan Philipp Bewersdorf, Thomas Prebet & Lohith Gowda. (2022) Azacitidine maintenance in AML post induction and posttransplant. Current Opinion in Hematology 29:2, pages 84-91.
Crossref
Smith Kungwankiattichai, Ben Ponvilawan, Claudie Roy, Pattaraporn Tunsing, Florian Kuchenbauer & Weerapat Owattanapanich. (2022) Maintenance With Hypomethylating Agents After Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis. Frontiers in Medicine 9.
Crossref
Jonathan A. Webster, Leo Luznik & Ivana Gojo. (2021) Treatment of AML Relapse After Allo-HCT. Frontiers in Oncology 11.
Crossref
Jan Philipp Bewersdorf, Cecily Allen, Abu-Sayeef Mirza, Alyssa A. Grimshaw, Smith Giri, Nikolai A. Podoltsev, Lohith Gowda, Christina Cho, Martin S. Tallman, Amer M. Zeidan & Maximilian Stahl. (2021) Hypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation–A Systematic Review and Meta-Analysis. Transplantation and Cellular Therapy 27:12, pages 997.e1-997.e11.
Crossref
Jan Philipp Bewersdorf, Martin S. Tallman & Maximilian Stahl. (2021) Maintenance therapies in acute myeloid leukemia: the renaissance of an old therapeutic concept. Current Opinion in Oncology 33:6, pages 658-669.
Crossref
Jia Liu, Zhong-Xing Jiang, Xin-Sheng Xie, Ding-Ming Wan, Wei-Jie Cao, Meng Wang, Zhen-Zhen Liu, Zhen-Kun Dong, Hai-Qiong Wang, Run-Qing Lu, Yin-Yin Zhang, Qian-Qian Cheng, Ji-Xin Fan, Wei Li, Fei He & Rong Guo. (2021) Maintenance Treatment With Low-Dose Decitabine After Allogeneic Hematopoietic Cell Transplantation in Patients With Adult Acute Lymphoblastic Leukemia. Frontiers in Oncology 11.
Crossref
Firas El Chaer, Uma BorateRémy Duléry, Shernan G. Holtan, Arjun Datt Law, Lori Muffly, Samah NassereddineRory M. Shallis, Kate StringarisJustin Taylor, Steven M. Devine, Mohamad MohtyChristopher S. Hourigan. (2021) Azacitidine maintenance after allogeneic hematopoietic cell transplantation for MDS and AML. Blood Advances 5:6, pages 1757-1759.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.